Somnomed Limited · ASX:SOM
Somnomed — H1 FY2016/17 Earnings Presentation
11 slides from Somnomed's earnings presentation, Feb 23, 2017
Slide 1: Investor Presentation Financial Year 2016/17 Half Year Review
For personal use only Investor Presentation Financial Year 2016/17 Half Year Review Investor Presentation | Slide 0
Slide 2: Disclaimer & Regulatory Disclosure
Disclaimer & Regulatory Disclosure For personal use only This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s
Slide 3: Global Highlights first half 2016/17
Global Highlights first half 2016/17 For personal use only SomnoMed • Global MAS sales volumes +14.9%; group revenues +11.5% o Good acceleration in Australia in second quarter o Consistent strong growth in Europe o Lower growth in the US linked to RSS launch • MAS gross margin improved from 68.5% to
Slide 4: Continuing expansion
Continuing expansion For personal use only Global unit sales growth Global revenue growth Units A$’000 $23.8m 33,309 units 25,000 35,000 30,000 20,000 25,000 Other 15,000 revenues 20,000 Units +20.6% +14.9% 15,000 10,000 MAS 10,000 revenues 5,000 +9.7% 5,000 0 0 2012/13 2013/14 2014/15 2015/16 2016/
Slide 5: Strengthening margins and profits
Strengthening margins and profits For personal use only MAS Gross Margin % EBITDA * % A$’000 69.3% 70 1,600 $1.4m 69 1,400 69 1,200 68 1,000 68 800 67 600 67 400 66 200 66 0 2012/13 2013/14 2014/15 2015/16 2016/17 2012/13 2013/14 2014/15 2015/16 2016/17 Half Year Half Year MAS Gross Margin EBITDA (0
Slide 6: Renew Sleep Solutions
Renew Sleep Solutions For personal use only • Strategic “Direct To Patient” channel opened • Dallas based executive team recruited • First two centres opened ahead of time and under budget • Initial patient capture in line with expectations and financial model • Five centres to operate by end of Jun
Slide 7: SomnoMed core business
SomnoMed core business North America – RSS and Managed Care expansion For personal use only • Transitional year with establishment of RSS caused some disturbance due to perceived channel conflict but shows signs of having stabilised (growth of 15.5% below our usual MAS growth rate of 20%) • Expansio
Slide 8: Summary Profit & Loss
Summary Profit & Loss For personal use only SomnoMed Financial Summary – AUD $000’s SomnoMed SomnoMed SomnoMed RSS Group FY16/17 FY15/16 FY16/17 FY16/17 FY16/17 1st H 1st H 1st H 1st H 1st H Group revenue 23,787 21,333 11.5% ** 23,787 - 23,787 Group gross margin 13,721 12,272 11.7% 13,721 (12) 13,70
Slide 9: Future of SomnoMed
Future of SomnoMed For personal use only Market fundamentals are very positive • Aging population and increasing obesity driving the incidence of OSA • Increased awareness of OSA and home diagnosis driving market growth • Patient CPAP non-compliance leads to the demand for alternatives and COAT™ is
Slide 10: Outlook second half 2016/17
Outlook second half 2016/17 For personal use only • SomnoMed global position very strong • Sales volumes expected to grow by over 20% • Renew Sleep Solutions to move forward aggressively and will become instrumental to strong growth in 2017/18 and beyond • Significant increase in US Managed Care ope
Slide 11: Contact details
Contact details For personal use only CHIEF EXECUTIVE OFFICER Mr. Derek Smith CHIEF FINANCIAL OFFICER Mr. Neil Verdal-Austin Address Level 3, 20 Clarke Street Crows Nest NSW 2065 Australia Telephone +61 (2) 9467 0400 Website www.somnomed.com.au Investor Presentation | Slide 10